Paper Details

  1. Home
  2. Paper Details

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.

Author: BanerjeeSubhashis, FoleyPeter, GirgisIhab G, GooderhamMelinda, GordonKenneth, KunduSudeep, MoritaAkimichi, PappKim, ThaçiDiamant

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Selective inhibition of TYK2 with BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 may be effective in treating psoriasis. METHODS: We conducted a phase 2, double-blind trial of a TYK2 inhibitor, BMS-986165, in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1806382

データ提供：米国国立医学図書館（NLM）

TYK2 Inhibition: A Potential New Weapon Against Psoriasis

Psoriasis, a chronic inflammatory skin condition, can be a challenging and often frustrating journey for patients. This Phase 2 trial investigates the potential of a selective TYK2 inhibitor, BMS-986165, as a novel treatment for moderate-to-severe psoriasis. The researchers conducted a double-blind trial, comparing the effectiveness of BMS-986165 at different dosages to placebo. Their findings indicate that BMS-986165 showed significant promise in clearing psoriasis, with higher dosages leading to greater improvements.

BMS-986165: A Powerful Ally in the Fight Against Psoriasis

The study demonstrates that BMS-986165, at dosages of 3mg daily and higher, effectively reduced psoriasis severity, offering a potential new treatment option for patients. However, further research is needed to evaluate its long-term safety and efficacy.

Finding Relief: A New Oasis in the Psoriasis Desert

For those living with psoriasis, finding the right treatment can be like searching for a hidden oasis in a vast and unforgiving desert. This study provides a glimmer of hope, suggesting that BMS-986165 could be a valuable addition to the existing treatment landscape. However, it's essential to consult with a dermatologist to discuss the potential benefits and risks associated with this medication.

Dr. Camel's Conclusion

This Phase 2 trial offers exciting new insights into the potential of TYK2 inhibition for treating psoriasis. BMS-986165, a selective TYK2 inhibitor, demonstrated significant efficacy in reducing psoriasis severity, offering a potential new treatment option. While further research is needed, the findings suggest that this medication could be a valuable tool in the fight against psoriasis. This research represents a promising step in the ongoing journey to find effective and safe treatments for this challenging skin condition.

Date :
  1. Date Completed 2018-10-22
  2. Date Revised 2021-10-19
Further Info :

Pubmed ID

30205746

DOI: Digital Object Identifier

10.1056/NEJMoa1806382

Related Literature

Article Analysis
・Effects of deucravacitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.